Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Identifieur interne : 000143 ( PubMed/Corpus ); précédent : 000142; suivant : 000144Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Auteurs : Juan Simon Rico-Mesa ; Averi White ; Allen S. AndersonSource :
- Current cardiology reports [ 1534-3170 ] ; 2020.
English descriptors
- KwdEn :
- Alveolar Epithelial Cells (metabolism), Angiotensin Receptor Antagonists (adverse effects), Angiotensin Receptor Antagonists (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (adverse effects), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Betacoronavirus, Comorbidity, Coronavirus (drug effects), Coronavirus (isolation & purification), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Diabetes Mellitus, Type 2 (complications), Diabetes Mellitus, Type 2 (epidemiology), Humans, Hypertension (complications), Hypertension (epidemiology), Pandemics, Peptidyl-Dipeptidase A (adverse effects), Peptidyl-Dipeptidase A (therapeutic use), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Practice Guidelines as Topic.
- MESH :
- chemical , adverse effects : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Peptidyl-Dipeptidase A.
- complications : Diabetes Mellitus, Type 2, Hypertension.
- drug effects : Coronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Diabetes Mellitus, Type 2, Hypertension, Pneumonia, Viral.
- isolation & purification : Coronavirus.
- metabolism : Alveolar Epithelial Cells.
- chemical , therapeutic use : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Peptidyl-Dipeptidase A.
- Betacoronavirus, Comorbidity, Humans, Pandemics, Practice Guidelines as Topic.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.
DOI: 10.1007/s11886-020-01291-4
PubMed: 32291526
Links to Exploration step
pubmed:32291526Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.</title><author><name sortKey="Rico Mesa, Juan Simon" sort="Rico Mesa, Juan Simon" uniqKey="Rico Mesa J" first="Juan Simon" last="Rico-Mesa">Juan Simon Rico-Mesa</name><affiliation><nlm:affiliation>Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</nlm:affiliation></affiliation></author><author><name sortKey="White, Averi" sort="White, Averi" uniqKey="White A" first="Averi" last="White">Averi White</name><affiliation><nlm:affiliation>Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Anderson, Allen S" sort="Anderson, Allen S" uniqKey="Anderson A" first="Allen S" last="Anderson">Allen S. Anderson</name><affiliation><nlm:affiliation>Department of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX, 78229, USA. Andersona4@uthscsa.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32291526</idno><idno type="pmid">32291526</idno><idno type="doi">10.1007/s11886-020-01291-4</idno><idno type="wicri:Area/PubMed/Corpus">000143</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000143</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.</title><author><name sortKey="Rico Mesa, Juan Simon" sort="Rico Mesa, Juan Simon" uniqKey="Rico Mesa J" first="Juan Simon" last="Rico-Mesa">Juan Simon Rico-Mesa</name><affiliation><nlm:affiliation>Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</nlm:affiliation></affiliation></author><author><name sortKey="White, Averi" sort="White, Averi" uniqKey="White A" first="Averi" last="White">Averi White</name><affiliation><nlm:affiliation>Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Anderson, Allen S" sort="Anderson, Allen S" uniqKey="Anderson A" first="Allen S" last="Anderson">Allen S. Anderson</name><affiliation><nlm:affiliation>Department of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX, 78229, USA. Andersona4@uthscsa.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Current cardiology reports</title><idno type="eISSN">1534-3170</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alveolar Epithelial Cells (metabolism)</term><term>Angiotensin Receptor Antagonists (adverse effects)</term><term>Angiotensin Receptor Antagonists (therapeutic use)</term><term>Angiotensin-Converting Enzyme Inhibitors (adverse effects)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Betacoronavirus</term><term>Comorbidity</term><term>Coronavirus (drug effects)</term><term>Coronavirus (isolation & purification)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Diabetes Mellitus, Type 2 (complications)</term><term>Diabetes Mellitus, Type 2 (epidemiology)</term><term>Humans</term><term>Hypertension (complications)</term><term>Hypertension (epidemiology)</term><term>Pandemics</term><term>Peptidyl-Dipeptidase A (adverse effects)</term><term>Peptidyl-Dipeptidase A (therapeutic use)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Diabetes Mellitus, Type 2</term><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Diabetes Mellitus, Type 2</term><term>Hypertension</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Alveolar Epithelial Cells</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Comorbidity</term><term>Humans</term><term>Pandemics</term><term>Practice Guidelines as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32291526</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1534-3170</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>04</Month><Day>14</Day></PubDate></JournalIssue><Title>Current cardiology reports</Title><ISOAbbreviation>Curr Cardiol Rep</ISOAbbreviation></Journal><ArticleTitle>Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.</ArticleTitle><Pagination><MedlinePgn>31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11886-020-01291-4</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.</AbstractText><AbstractText Label="RECENT FINDINGS">Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated. Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rico-Mesa</LastName><ForeName>Juan Simon</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Averi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Allen S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX, 78229, USA. Andersona4@uthscsa.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Cardiol Rep</MedlineTA><NlmUniqueID>100888969</NlmUniqueID><ISSNLinking>1523-3782</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056809" MajorTopicYN="N">Alveolar Epithelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ACE2 receptor</Keyword><Keyword MajorTopicYN="Y">ACEI</Keyword><Keyword MajorTopicYN="Y">ARB</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-COV 2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32291526</ArticleId><ArticleId IdType="doi">10.1007/s11886-020-01291-4</ArticleId><ArticleId IdType="pii">10.1007/s11886-020-01291-4</ArticleId><ArticleId IdType="pmc">PMC7154066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacol Ther. 2010 Oct;128(1):119-28</Citation><ArticleIdList><ArticleId IdType="pubmed">20599443</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Compr Physiol. 2014 Jul;4(3):1201-28</Citation><ArticleIdList><ArticleId IdType="pubmed">24944035</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pharmacol Res. 2017 Nov;125(Pt A):21-38</Citation><ArticleIdList><ArticleId IdType="pubmed">28619367</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Allergy. 2020 Feb 19;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2020 May;92(5):491-494</Citation><ArticleIdList><ArticleId IdType="pubmed">32056249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Hypertens. 2015 Jan;28(1):15-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24842388</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E004</Citation><ArticleIdList><ArticleId IdType="pubmed">32120458</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Saudi Med. 2016 Jan-Feb;36(1):78-80</Citation><ArticleIdList><ArticleId IdType="pubmed">26922692</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trop Med Int Health. 2020 Mar;25(3):278-280</Citation><ArticleIdList><ArticleId IdType="pubmed">32052514</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Circulation. 2005 May 24;111(20):2605-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMJ. 2020 Feb 28;368:m810</Citation><ArticleIdList><ArticleId IdType="pubmed">32111649</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Respir Med. 2020 Feb 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Conn Med. 1965 Oct;29(10):710-1</Citation><ArticleIdList><ArticleId IdType="pubmed">4284109</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222</Citation><ArticleIdList><ArticleId IdType="pubmed">32164092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000143 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000143 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32291526
|texte= Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32291526" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |